Regulatory context
Regulatory context; not efficacy evidence
No matched controlled clinical study of this exact preparation was verified in this source audit.
Reported findings. Background context only. Matched evidence for the exact marketed formulation is not established by this reference.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Unknown in reviewed excerpt; absence of mention is not safety evidence.
Limits. Related-compound evidence is contextual only. Commercial names, modifications and routes do not establish clinical equivalence.
Preparation: Source preparation; commercial equivalence unverified. Route: Unknown in reviewed excerpt; do not infer.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.
Lab or animal research
Peptide Derivatives of the Zonulin Inhibitor Larazotide (AT1001) as Potential Anti SARS-CoV-2: Molecular Modelling, Synthesis and Bioactivity Evaluation.
Cultured Vero and HEL cells, not treated patients.
Reported findings. Weak cell-based activity in one studied strain.
Nonresponse. Activity varied by strain; other studied strain and HCMV outcomes did not demonstrate activity within the tested range.
Harms. Cell-morphology alteration and growth inhibition occurred; broad safety is not established.
Limits. Does not establish human gut benefit, clinical antiviral efficacy or human safety. Current supplier title says N-Acetyl while displayed sequence and acetate identity do not document both terminal modifications; exact stock equivalence unresolved.
Preparation: Compound 2 Ac-GGVLVQPG-NH2, both N-acetylated and C-terminal amidated; current marketed capsule chemistry unresolved. Route: Direct cell-culture exposure; no human administration.
Read original source ↗Editorial review 2026-10-09. Clinician review pending.